IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00 a.m. ET on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback